Comparing the current results to its competitors, Sagimet Biosciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 22.18 %, recorded in the same quarter.
Sagimet Biosciences Inc 's Comment on Competition and Industry Peers
The company operates in a highly competitive biopharmaceutical industry with numerous competitors developing compounds targeting similar indications. Notable competitors include Madrigal Pharmaceuticals, Inc., which has received FDA and European Commission approvals for resmetirom (Rezdiffra) for treating MASH, and Novo Nordisk A/S, which obtained FDA approval for Wegovy (semaglutide) for MASH treatment. Other multinational pharmaceutical and biotechnology companies in the competitive landscape include Altimmune, Inc., AstraZeneca, Boehringer Ingelheim, Zealand Pharma, Eli Lilly and Company, Galmed Pharmaceuticals Ltd., Gilead Sciences, Inc., GSK plc (which acquired Boston Pharmaceuticals in 2025), Inventiva S.A., Merck & Co., Inc., Pfizer Inc., Roche Holdings, Inc. (which acquired 89bio, Inc. in 2025), Terns Pharmaceuticals, Inc., Viking Therapeutics, Inc., and Zydus Therapeutics Inc. The company also acknowledges that smaller or earlier-stage companies, particularly through collaborations, may represent significant competition. Key factors influencing competition include efficacy, safety, tolerability, dosing convenience, price, generic competition, and reimbursement. The company’s drug candidate denifanstat may compete with other drug classes and mechanisms but could be used alone or in combination due to its complementary mechanism. Additionally, the company holds a license agreement with Ascletis Pharma, a biotechnology company based in Hangzhou, China.
November 18, 2024
: Sagimet Biosciences Inc. recently presented clinical data on its lead compound, denifanstat, at the American Association for the Study of Liver Diseases (AASLD) 2024 meeting. The findings from the subset analysis of the Phase 2 FASCINATE-2 trial suggested that denifanstat has significant potential in improving liver fibrosis in patients with difficult-to-treat Metabolic Associated Steatotic Liver Disease (MASH). However, the company also reported a stagnation in revenue for the third quarter of 2024, contrasting with the overall financial growth experienced by its competitors. This article outlines the clinical advancements and financial challenges facing Sagimet Biosciences in the current market context. ...
May 7, 2024
Sagimet Biosciences Inc., a California-based clinical-stage biopharmaceutical company specializing in the development of novel fatty acid synthase (FASN) inhibitors, announced that it will present verbalized findings from its Phase 2b FASCINATE-2 trial of denifanstat at the upcoming European Association for the Study of the Liver (EASL) International Liver Congress 2024. The congress is set to take place from 5-8 June, 2024 in Milan, Italy.This announcement made on May 07, 2024 signifies the company s major progress made in its endeavors to target dysfunctional metabolic and fibrotic pathways in disease management. The presentation will revolve around the use of denifanstat, a novel FASN inhibitor, in a path...
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Sagimet Biosciences inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Sagimet Biosciences inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
